Lonza Group AG LONN:SIX; LO3:FSE; LZAGF:OTCPK

Notable Quotes

"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More�>

"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More�>

"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More�>

"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More�>

"ACRX has a revolutionary painkiller, Zalviso; the stock is a very good buy, with lots of upside." (2/20/14) AcelRx Pharmaceuticals Inc. - The Life Sciences Report Interview with Chen Lin More�>

Companies

Lonza Group AG

TICKER: LONN:SIX; LO3:FSE; LZAGF:OTCPK

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.